6.3.4.15	(2'R,6'S)-9-[6'-([[N-(D-biotinoyl)sulfamoyl]oxy]methyl)morpholin-2'-yl]adenine	nucleoside-based inhibitor, KD value 0.324 nM	222733	
6.3.4.15	(3aS,4S,6aR)-4-(5-[1-[3-(naphthalen-2-yloxy)propyl]-1H-1,2,3-triazol-4-yl]pentyl)tetrahydro-1H-thieno[3,4-d]imidazol-2(3H)-one	-	193809	
6.3.4.15	(3aS,4S,6aR)-4-(5-[1-[4-(naphthalen-1-yloxy)butyl]-1H-1,2,3-triazol-4-yl]pentyl)tetrahydro-1H-thieno[3,4-d]imidazol-2(3H)-one	-	193806	
6.3.4.15	(3aS,4S,6aR)-4-(5-[1-[4-(naphthalen-2-yloxy)butyl]-1H-1,2,3-triazol-4-yl]pentyl)tetrahydro-1H-thieno[3,4-d]imidazol-2(3H)-one	-	193807	
6.3.4.15	(3aS,4S,6aR)-4-[-[1-[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl]triazol-4-yl]pentyl]-1,3,3a,4,6,6ahexahydrothieno[3,4-d]imidazol-2-one	competitive inhibitor	194629	
6.3.4.15	(3aS,4S,6aR)-4-[4-[1-[[(3aR,4R,6R,6aR)-4-(6-aminopurin-9-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methyl]triazol-4-yl]butyl]-1,3,3a,4,6,6a-hexa hydrothieno[3,4-d]imidazol-2-one	-	194630	
6.3.4.15	(3aS,4S,6aR)-4-[5-[1-(4-phenoxybutyl)-1H-1,2,3-triazol-4-yl]pentyl]tetrahydro-1H-thieno[3,4-d]imidazol-2(3H)-one	-	193805	
6.3.4.15	(3aS,4S,6aR)-4-[5-[1-[[(3aR,4R,6R,6aR)-4-(6-aminopurin-9-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methyl]triazol-4-yl]pentyl]-1,3,3a,4,6,6a-hexa hydrothieno[3,4-d]imidazol-2-one	-	194631	
6.3.4.15	(3aS,4S,6aR)-4-[5-[3-[[(3aR,4R,6R,6aR)-4-(6-aminopurin-9-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methyl]triazol-4-yl]pentyl]-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-2-one	-	194633	
6.3.4.15	(3aS,4S,6aR)-4-[6-[1-[[(3aR,4R,6R,6aR)-4-(6-aminopurin-9-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methyl]triazol-4-yl]hexyl]-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-2-one	-	194632	
6.3.4.15	2'-amino-5'-[N-(D-biotinoyl)sulfamoyl]amino-3',5'-dideoxyadenosine	nucleoside-based inhibitor, KD value 0.627 nM	222968	
6.3.4.15	2-(4-[5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentyl]-1H-1,2,3-triazol-1-yl)ethyl 2,2-dimethylpropanoate	-	193789	
6.3.4.15	3-(2-oxo-1,3-benzoxazol-3(2H)-yl)-N-phenylpropanamide	inhibitor identified by molecular docking, glide score -7.49, glide energy -40.64 kcal/mol	223216	
6.3.4.15	5-chloro-3-[4-(4-[5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentyl]-1H-1,2,3-triazol-1-yl)butyl]-1,3-benzoxazol-2(3H)-one	not inhibitory to human enzyme at 0.08 mM	223550	
6.3.4.15	5-methyl-3-[3-(4-[5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentyl]-1H-1,2,3-triazol-1-yl)propyl]-1,3-benzoxazol-2(3H)-one	-	193810	
6.3.4.15	5-methyl-3-[4-(4-[5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentyl]-1H-1,2,3-triazol-1-yl)butyl]-1,3-benzoxazol-2(3H)-one	competitive inhibitor versus biotin	193808	
6.3.4.15	5-methyl-3-[4-(4-[5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentyl]-1H-1,2,3-triazol-1-yl)butyl]-1,3-benzoxazol-2(3H)-one	not inhibitory to human enzyme at 0.08 mM	193808	
6.3.4.15	9-[2'-azido-5'-O-[N-(D-biotinoyl)sulfamoyl]-2'-deoxy-beta-D-arabinofuranosyl]adenine	nucleoside-based inhibitor, KD value 0.027 nM. Strongest binding inhibitor in series	223680	
6.3.4.15	ATP	-	4	
6.3.4.15	biotin acetylene	i.e. (3aS,4S,6aR)-4-hept-6-ynyl-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-2-one	194634	
6.3.4.15	biotinol-5'-AMP	-	193428	
6.3.4.15	biotinyl-5'-AMP	selective inhibitor	30956	
6.3.4.15	diphosphate	endproduct inhibition	17	
6.3.4.15	GLNDIFEAQKIEWH	i.e. Schatz' peptide, synthetic biotinable minimal peptide, competitively inhibits self-biotinylation	85633	
6.3.4.15	glycerol	inhibits the recombinant enzyme at 10%	135	
6.3.4.15	MgAMP	endproduct inhibition, mechanism of inhibition, overview	13347	
6.3.4.15	N-(2-methylphenyl)-2-(2-oxo-1,3-benzoxazol-3(2H)-yl)acetamide	inhibitor identified by molecular docking, glide score -7.34, glide energy -37.68 kcal/mol	223905	
6.3.4.15	NaCl	inhibits the purified enzyme at 0.1 M, but not the immobilized enzyme in crude extract of recombinant yeast cells	42